Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC2R | Q01718 | 14/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atumelnant SCHEMBL29932180 | 1.00 | MC2R (1.00) | MC2RHTR1BUGCG | |
| Atumelnant SCHEMBL29931824 | 1.00 | MC2R (1.00) | MC2RHTR1BUGCG | |
| Atumelnant SCHEMBL22382763 | 1.00 | MC2R (1.00) | MC2RHTR1BUGCG | |
| Atumelnant SCHEMBL30897579 | 0.96 | MC2R (0.93) | MC2RHTR1BUGCG | |
| Atumelnant SCHEMBL30897580 | 0.96 | MC2R (0.93) | MC2RHTR1BUGCG | |
| Atumelnant SCHEMBL30897581 | 0.94 | MC2R (0.89) | MC2RHTR1BUGCG | |
| SCHEMBL21725665 | 0.92 | MC2R (0.86) | MC2RHTR1B | |
| SCHEMBL21700589 | 0.91 | MC2R (1.00) | MC2RHTR1B | |
| SCHEMBL21700749 | 0.90 | MC2R (0.97) | MC2RHTR1B | |
| SCHEMBL23251436 | 0.89 | MC2R (0.79) | MC2RHTR1BUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | claimed |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-09-12 | — | — | US | claimed |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-04-04 | — | — | US | claimed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | claimed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | claimed |
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250367190-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASE | CRINETICS PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240208963-A1 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | Crinetics Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208963-A1 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | Crinetics Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024130091-A1 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208963-A1 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | MC3R, MC2R, MC5R | MC2R 2/4885HTR1B 37/4885UGCG 3862/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-20250367190-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASE | MC2R, MC3R, MC5R | MC2R 1/4885HTR1B 212/4885UGCG 3536/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885UGCG 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.